At MSD, we're following the science to tackle some of the world's greatest health threats. Get a glimpse of how we work to improve lives.

MSD is a Founding Industry Member of Our Future Health, the UK’s largest health research programme, which aims to prevent, detect and treat disease earlier. The programme will provide new ways to predict with better accuracy who is at higher risk of diseases and would benefit from faster access to screening and prevention interventions.

If you are a health care professional and have an enquiry about supply of MSD products, please contact: Phone: 0208 1548001 (0208 1548000 during holidays) Email: [email protected]. For updates on our current product shortages/divestments please click here

We use the power of leading-edge science to save and improve lives around the world. Step inside MSD Research Laboratories (MRL) where our mission to save and improve lives through research and development begins. See all R&D locations

Today, MSD has a range of prescription products in key therapeutic areas, such as cardiovascular disease, diabetes, oncology, vaccines and infectious diseases. Please note that due to the Company spin off, former MSD products in women’s health, legacy brand and biosimilars have been transferred to Organon & Co.

A leading people-first employer: Top Employer UK/Europe 2024. The Top Employers Institute is the global authority on recognising excellence in people practices and for the seventh year running we have been recognised for demonstrating care for the development and well-being of our people. What makes us a Top Employer?

This long-term lease will allow MSD to develop a Discovery Centre and UK HQ with the aim of ensuring that innovation is at the heart of drug discovery, whilst its position in the Kings Cross area will provide proximity to leading UK academic and industry research, access to Europe, as well as offer unique collaboration opportunities.

MSD in the UK have published a policy consensus statement, A Shared Vision for Pulmonary Arterial Hypertension in the UK, with recommendations driven by expert insights outlining a unified vision for the future of pulmonary arterial hypertension (PAH) care in the UK.

Through a number of activities, MSD is committed to partnering with the local and national health system to strengthen the UK’s response across vaccine-preventable diseases, by reducing inequalities in access to immunisation programmes.

Health inequalities have a direct impact on the risk of getting cancer, the speed with which someone is diagnosed, and their likelihood of surviving – MSD’s October 2022 report, Levelling up: what does it mean for the less survivable cancers in England?, analysed national data from some of the least survivable cancers and found that only 49 ...